Back
42
Day Range
$96.59
$98.83
52-Week Range
$92.77
$127.99
Volume
772,761
50D / 200D Avg
$102.88
/
$113.90
Prev Close
$95.86
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 17.3 | 0.4 |
| P/B | 4.0 | 2.9 |
| ROE % | 25.1 | 3.8 |
| Net Margin % | 9.5 | 3.9 |
| Rev Growth 5Y % | 10.3 | 10.0 |
| D/E | 1.1 | 0.2 |
Analyst Price Target
Hold
$151.50
+55.4%
Low: $150.00
High: $153.00
Forward P/E
16.5
Forward EPS
$5.92
EPS Growth (est.)
+0.0%
Est. Revenue
6.4 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2029 |
$7.69
$7.65 – $7.76
|
7.9 B | 1 |
| FY2028 |
$7.04
$6.95 – $7.12
|
7.5 B | 2 |
| FY2027 |
$6.47
$6.05 – $6.65
|
6.9 B | 8 |
Key Takeaways
Revenue grew 10.27% annually over 5 years — strong growth
Earnings grew 24.25% over the past year
ROE of 25.14% indicates high profitability
Generating 439.20M in free cash flow
PEG of 0.78 suggests growth is underpriced
ROIC of 15.33% — excellent capital efficiency
Growth
Revenue Growth (5Y)
10.27%
Revenue (1Y)10.46%
Earnings (1Y)24.25%
FCF Growth (3Y)28.09%
Quality
Return on Equity
25.14%
ROIC15.33%
Net Margin9.54%
Op. Margin17.74%
Safety
Debt / Equity
1.11
Current Ratio1.08
Interest Coverage8.55
Valuation
P/E Ratio
17.33
P/B Ratio4.02
EV/EBITDA11.80
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10.46% | Revenue Growth (3Y) | 11.18% |
| Earnings Growth (1Y) | 24.25% | Earnings Growth (3Y) | 26.83% |
| Revenue Growth (5Y) | 10.27% | Earnings Growth (5Y) | 8.26% |
| Profitability | |||
| Revenue (TTM) | 5.94B | Net Income (TTM) | 566.20M |
| ROE | 25.14% | ROA | 7.99% |
| Gross Margin | 21.72% | Operating Margin | 17.74% |
| Net Margin | 9.54% | Free Cash Flow (TTM) | 439.20M |
| ROIC | 15.33% | FCF Growth (3Y) | 28.09% |
| Safety | |||
| Debt / Equity | 1.11 | Current Ratio | 1.08 |
| Interest Coverage | 8.55 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 17.33 | P/B Ratio | 4.02 |
| P/S Ratio | 1.65 | PEG Ratio | 0.78 |
| EV/EBITDA | 11.80 | Dividend Yield | 0.01% |
| Market Cap | 9.81B | Enterprise Value | 12.42B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.94B | 5.37B | 4.80B | 4.35B | 4.01B |
| Net Income | 566.20M | 455.70M | 352.00M | 271.00M | 412.20M |
| EPS (Diluted) | 5.55 | 4.46 | 3.47 | 2.70 | 4.11 |
| Gross Profit | 1.29B | 2.23B | 1.98B | 1.75B | 1.70B |
| Operating Income | 1.05B | 864.50M | 1.72B | 630.20M | 659.40M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7.09B | 6.53B | 6.10B | 5.64B | 6.86B |
| Total Liabilities | 3.81B | 3.69B | 3.81B | 3.77B | 4.47B |
| Shareholders' Equity | 2.44B | 2.07B | 1.65B | 1.31B | 1.91B |
| Total Debt | 2.71B | 2.71B | 2.93B | 2.99B | 3.48B |
| Cash & Equivalents | 102.90M | 85.40M | 104.20M | 21.80M | 49.40M |
| Current Assets | 905.90M | 886.90M | 841.80M | 717.20M | 921.40M |
| Current Liabilities | 836.40M | 841.00M | 656.40M | 575.90M | 748.80M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#233 of 326
Recent Activity
Entered
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026